<DOC>
	<DOCNO>NCT02911948</DOCNO>
	<brief_summary>Comparing efficacy safety insulin degludec/liraglutide insulin degludec combination metformin Japanese subject type 2 diabetes mellitus inadequately control basal pre-mix/combination insulin therapy oral anti-diabetic drug</brief_summary>
	<brief_title>A Double-blinded Trial Comparing Efficacy Safety Insulin Degludec/Liraglutide Insulin Degludec Both Combination With Metformin Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Pre-mix/Combination Insulin Therapy Oral Anti-diabetic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Male female Japanese subject , age least 20 year time signing informed consent T2DM ( type 2 diabetes mellitus ) subject ( diagnose clinically ) least 6 month prior screen HbA1c ( glycosylated haemoglobin ) 7.511.0 per cent [ 58 mmol/mol97 mmol/mol ] ( inclusive ) central laboratory analysis Subjects stable daily insulin dos least 60 day prior screen administer twice daily , either basal insulin ( e.g . IDeg , insulin glargine , insulin detemir , NPH insulin ) premix/combination insulin ( e.g . biphasic insulin aspart , insulin degludec/insulin aspart ) . Total daily insulin dose previous 60 day within 2050 unit , inclusive , day screening , fluctuation plus/minus 20 per cent within 60 day prior screen acceptable . The specified insulin treatment administer combination stable daily dose metformin within current approve Japanese label least 60 day prior screen additionally , antidiabetic treatment without stable daily dose one follow OADs ( oral antidiabetic drug ) : SU ( sulfonylurea ) , glinides , alphaglucosidase inhibitor , SGLT2i ( sodium glucose cotransporter 2 inhibitor ) TZD ( thiazolidinedione ) within current approve Japanese label least 60 day prior screen Body Mass Index ( BMI ) equal 23 kg/m^2 Receipt investigational medicinal product ( IMP ) within 30 day screen Use antidiabetic drug period 60 day screen ( except premix/ combination basal insulin , metformin , SU , glinides , Î±GI , SGLT2i , TZD ) anticipate change concomitant medication , investigator opinion could interfere glucose metabolism ( e.g . systemic corticosteroid bolus insulin ) Treatment glucagonlike peptide1 ( GLP1 ) receptor agonist last 60 day prior screen furthermore , discontinuation GLP1 receptor agonist point time must due safety concern , tolerability issue lack efficacy , judge investigator Treatment dipetidyl peptidase4 ( DPP4 ) inhibitor last 60 day prior screen Impaired liver function , define alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) equal 2.5 time upper limit normal Renal impairment estimate Glomerular Filtration Rate ( eGFR ) 60 mL/min/1.73m^2 per Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) Screening calcitonin equal 50 ng/L History pancreatitis ( acute chronic ) Personal family history medullary thyroid carcinoma ( MTC ) multiple endocrine neoplasia type 2 ( MEN 2 ) Subjects presently classified New York Heart Association ( NYHA ) Class IV</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>